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Unique properties on the nanoscale, such as high surface-area-to-volume ratio and 
biocompatible size, allow nanoparticles to act as a platform for drug delivery. A modular 
approach to developing nanoparticles (NPs) as anticancer therapeutics allows for individualized 
therapy. So long as biomarkers on the cancer cell are present, the nanovehicle can selectively 
target the cancer cell and reduce cytotoxicity to the body at large. The goal of this project is to 
synthesize an iron oxide core-gold shell (Au-FexOy) nanovehicle that will image, target, and 
selectively destroy pancreatic cancer cells. Two types of iron oxide cores were used: one 
synthesized following Kang et al. and the other purchased from Ferrotec. To begin the formation 
of the gold shell, the core was functionalized with (3-aminopropyl)-trimethoxysilane (APTMS). 
Success of this procedure was determined through FT-IR. Next, 2 nm Au NPs were added to the 





. This was done using a commercially available kit: Gold Enhance
TM
. Final 
products were characterized with UV-Vis spectroscopy, dynamic light scattering, and 
transmission electron microscopy. Tests confirmed that the peak visible in the products’ UV-Vis 
spectra were from Au-FexOy NPs. Varying concentrations of high purity nitric acid were used to 
determine at what concentration would not digest Au NPs, only FexOy NPs. Results indicate that 
more APTMS and multiple exposures of 2 nm Au NPs were optimal. More work must be done to 
determine the effects of Gold Enhance
TM
 as well as to ensure reproducibility of results. Overall, 
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1.1  Pancreatic Cancer 
Of the estimated 1,638,910 new cancer cases in 2012 in the US, 2.6% are expected to 
have been cases of pancreatic ductal adenocarcinoma, more commonly known as pancreatic 
cancer.
1
 Despite the relatively low prevalence of pancreatic cancer as compared to other types of 
cancer, 6.5% of the cancer-related deaths in 2012 were as a result of this specific cancer.
1
 For all 
stages combined, the 1-year and 5-year survival rates for those diagnosed with pancreatic cancer 
are 26% and 6%, respectively.
2
 This poor prognosis is a consequence of late detection because of 
delayed and unspecific symptoms in patients at the time of first diagnosis.
3,4
 Blood tests can be 
used for detection; however, the levels of CA 19-9, a substance released into the blood by 
exocrine pancreatic cancer cells, are not high enough for detection until the cancer is in its later 
stages.
1
 More than half of patients are diagnosed at an advanced stage, for which the 5-year 
survival rate is 2%.
2
 As the disease presents few symptoms and tumors cannot be palpitated by 
physicians, there are no reliable methods of early detection.
3
 Furthermore, treatment options are 
as of now limited to surgical resection, radiation therapy, and non-selective chemotherapy, all of 




As part of the digestive system, the pancreas 
produces enzymes and hormones to break down food; 
Figure 1 illustrates the pancreas’s position behind the 
stomach and in front of the spine. Its close proximity to 
and connections with other vital organs render current 
treatment options hazardous. For example, the most 
common procedure for removal of pancreatic cancer 
Figure 1: Overall view of abdomen 




tumors, pancreaticoduondenectomy, also 
known as Whipple procedure, is regarded as 
one of the most difficult operations.
1
 Figure 
2 shows the reconstruction made by the 
Whipple procedure, which entails removing 
the head of the pancreas, the gallbladder, a 
portion of the small intestine (dudodenum) 
and a part of the bile duct. Even when 
carried out by experienced surgeons, patients may suffer complications as a result of this 
procedure. These may include infections, bleeding, leaking from the various connections made 
after resectable tumors were removed, and difficulties with the stomach emptying itself after 
eating.
1
 Owing to the large percentage of tumors that have metastasized by the time of diagnosis, 
surgery is often employed to palliate symptoms rather than to wholly cure the patient. When it is 
used to cure pancreatic cancer, and it is the only chance for cure, this procedure has a cure rate of 
only 10–15%.5 Despite the danger of the operation, the host of side effects, and the low cure rate, 
surgery continues to be a treatment method even in palliative approaches.  
Radiation similarly has a number of harmful side effects, such as mild skin irritation 
(similar to a sun burn), nausea, vomiting, diarrhea, fatigue, poor appetite, and weight loss, while 
also not being a curative option.
1
 Furthermore, radiation therapy lowers white blood cell count 
and can increase the risk of infections. Radiation can be combined with chemotherapy when the 
tumors are too widespread to be surgically removed.
1
 Although radiation works better in 
conjunction with chemotherapy, the combination of the two gives rise to more severe side 
effects.
1
   
Figure 2: The Whipple procedure is a surgical operation to 







As cancer cells inherently divide rapidly, chemotherapy targets cells with this property; 
in so doing, the therapy kills cancer cells as well as healthy cells that also divide rapidly. Like 
surgery and radiation therapy, it has minimal curative properties for pancreatic cancer as well as 
a list of possible side effects; for example, nausea, vomiting, loss of appetite, hair loss, mouth 
sores, and diarrhea. The specific side effects depend on the type of drug, amount taken, and the 
length of treatment. The drug most commonly used is gemcitabine.
1
 Shown in Figure 3, 
gemcitabine or 2’,2’-difluoro-2’-deoxycytidine is a potent 
pyrimidine antimetabolite, which inhibits cellular replication of 
DNA and RNA.
6
 This liquid drug is administered intravenously 
and has the added side effects of the swelling of feet or legs or 
weight gain as a result of fluid retention, appearance of flu-like 
symptoms, and a compromised immune system.
1
 Other possible 
chemotherapies include fluorouracil and capecitabine. Current 
trials have been investigating these drugs in combination with one another and, particularly, in 
combination with gemcitabine.
7,8,9
 Although even when conjugated to a biocompatibility agent, 
such as polyethylene-glycol (PEG), gemcitabine continues to be highly cytotoxic.
10
  
The continual increase in the biological understanding of pancreatic cancer has led to the 
clinical development of more targeted strategies.
11
 In recent years, there have been investigations 
into growth factor inhibitors, anti-angiogenesis, radioimmunoconjugates, and gene therapy. 
Growth factor inhibitors target molecules on a cancer cell’s surface that help them mature, 
whereas anti-angiogenssis blocks the growth of new blood vessels in a cancer cell, thereby 
starving the tumor. Radioimmunoconjugates similarly encourage cell death, but through a 
monoclonal antibody conjugated to a radioactive nuclide. Gene therapy achieves cancer cell 
Figure 3: Chemical structure of 
gemcitabine (2’,2’-difluoro-2’-
deoxycytidine), a chemotherapeutic 
drug that arrests tumor growth 
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death by increasing the concentration of TNF-α, which regulates immune cells and induces 
apoptotic cell death. However, these approaches are currently not widely used. 
The asymptomatic nature of pancreatic cancer, lack of adequate detection methods, and 
limited scope of effective treatment options lend to the need for alternative methods.  
1.2 Nanotechnology and Medicine 
Nanotechnology centers on materials and structures with at least one dimension on the 1 
to 100 nanometer scale. On this scale, materials possess unique properties and characteristics that 
they do not have on the atomic or macro-level.
12,13
 The dependence of a nanoparticle’s properties 
on its size, as a result of quantum confinement, allows for the tuning of said material’s 
properties. The small size of the nanoparticle lends to a high surface-to-volume ratio, where a 
variety of moieties can attach; this enables the nanoparticle to achieve multiple functions.
13-14
 
Such examples may include therapeutic or targeting agents. A nanoparticle’s ability to act as a 




However, to allow for more blood circulation time and optimal efficacy, nanoparticle size 
must be between 10 and 100 nm.
15,17 
Additionally, a narrow range of particle size distribution 
ensures uniform physical and chemical properties.
17
 Larger particles with diameters greater than 
200 nm are sequestered by the reticuloendothelial system (RES), which ingests bacteria or 
colloidal particles. Those with diameters less than 10 nm are removed through the kidneys as 
well as gaps between the endothelial cells (extravasations). Diameters of 10 to 100 nm, therefore, 
allow the nanoparticles to be small enough to evade the RES while also penetrating the small 
capillaries within body tissues. 
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The application of nanotechnology to drug delivery is widely expected to expand the 
scope of therapeutic approaches of pharmaceutical and biotechnology industries.
18
 The 
attachment of drugs to nanoparticles allows for the reduction of drug doses and potential side 
effects on healthy tissues. The nanoparticle targets the tumors either through targeting agents 
attached to its surface or through the enhanced permeability and retention (EPR) effect. The EPR 
effect is the phenomenon where nanoparticles of specific sizes accumulate in the tumor as a 
result of abnormalities in the tumor vasculature. Figure 4 shows the clear reduction of cytotoxic 
effects as well as damage to healthy cells. This reduction is especially relevant to illnesses, such 
as pancreatic cancer, where chemotherapy is needed but necessitates limited dosage owing to the 
drugs’ toxicity.19 Tested cancer-targeting ligands include monoclonal antibodies, peptides, 
polyunsaturated fatty acids, polysaccharides; all of which induce receptor-mediated endocytosis 
to enter the tumor cell.
20
 Furthermore, the high morbidity and invasive nature associated with 
surgical removal of tumors renders this treatment unsuitable for treatment of small, poorly 
defined metastases or tumors embedded within vital organs.
21
 Nanoparticles’ ability to be 
functionalized by malignant cell targeting and drug delivery surfactants provides a minimally 
invasive, targeted alternative to surgery, radiation, and chemotherapy.  
 
Figure 4: This comparison of drug distribution in the body illustrates the specificity between the free drug and those 





1.3 Inorganic Nanoparticles 
Numerous types of nanocarriers, shown in Figure 5, have been investigated as possible 
vehicles for drug delivery. One such example is liposomes. First described in the 1960s, this 
nanoscale drug delivery system was the first of its kind.
16
 The system uses lipids to fashion a 
nanoparticle by forming a bilayer based on hydrophobic interactions. Liposomes encapsulate 
their load in the inner aqueous phase or in the lipid bilayer. The overall system is shown in 
Figure 5; however, the figure does not illustrate the lipid bilayer. Polymer-drug conjugates, on 
the other hand, attach the chemotherapeutic drugs to the polymer chain through side-chain 
grafting. This system is one of the most investigated drug delivery systems and is currently in 
clinical trials.
16
 This research, however, will primarily focus on inorganic nanoparticles, more 
specifically those containing a magnetic metal (iron oxide) and a noble metal (gold). 
 
1.3.1. Iron Oxide Nanoparticles 
The physics and surface chemistry of nanoscale magnetic particles makes them of high 
interest for labeling, imaging, delivery, and other therapeutic tools for medicine.
22
 Magnetic 





nanoparticles can be functionalized by drugs, proteins, and antibodies, to name a few examples, 
and can be directed at an organ, tissue, or tumor using an external magnetic field or targeting 
moieties.
23
 Their ability to be imaged through magnetic resonance imaging (MRI), by 




Iron oxide nanoparticles, specifically, have been investigated for the past 40 years and 
used, for example, as a MRI contrast enhancement, for tissue repair, and drug delivery.
17
 The 
most common forms of iron oxide are magnetite (Fe3O4) and maghemite (γ-Fe2O3). Both possess 
cubic inverse spinel crystal structures and, when between approximately 6–15 nanometers, 
contain magnetic moments that can align with an external magnetic field whereby the particles 
consequently amplify the field.
23
 This property, superparamagnetism, allows this material to be 
used as an MRI contrast agent. As the name suggests, superparamagnetic particles undergo a 
greater degree of magnetization induced by an external magnetic field than paramagnetic 
particles. Magnetite and maghemite, as superparamagnetic particles, are not permanently 
magnetized upon the removal of an external magnetic field, whereas ferromagnetic particles 
maintain their magnetization even in the absence of a magnetic field. Additionally, surface 
functionalizations minimize the remnants of magnetite or maghemite magnetization, with 
maghemite initially displaying a weaker magnetization.
25,26
 These particles are of particular 
interest because their physical and chemical properties can be adjusted by modifications of their 
surfaces.
17,27
 The surfaces are altered through the creation of a shell, whether inorganic metallic 
(e.g. gold) or oxide (e.g. silica), as well as through conjugation to polymers, such as polyethylene 
glycol (PEG). The nanoshell allows the nanoparticle to be suitable for further functionalization 
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of various bioactive molecules.
17
 Overall, these surface functionalizations help to stabilize the 
material for in vivo and in vitro testing.  
In terms of cytotoxicity, iron oxide is biodegradable, 
but needs the assistance of surface modifications to increase its 
lifetime within the body.
23
 Iron oxide is eventually recycled by 
cells for iron metabolism, making it a good alternative to 
cytotoxic chemotherapeutic agents.
23, 28
 By itself, an iron oxide nanoparticle of 12 nm has a half-
life of 2–3 hours in humans, depending on the dose administered, before being taken up by the 
liver; however, the addition of the biocompatibility agent, polyethylene glycol, as shown in 
Figure 6 for example, helps to increase this residence time in vivo.
23,29,30
 Polyethylene glycol 
(PEG) is hydrophilic, non-antigenic, and non-immunogenic. Its biocompatibility properties were 
exemplified when Gupta et al. injected PEG-functionalized FexOy nanoparticles into human 
dermal fibroblasts (cells that live within the dermis) and 99% of the cells were viable for a dose 




Surface modifications also help to reduce aggregations of iron oxide, which in turn help 
the biodistribution of the particles. Iron oxide nanoparticles tend to agglomerate and form large 
clusters as a result of hydrophobic interactions amongst themselves,
23





. The latter process involves the growth of larger crystals, in this case 
nanoparticles, by the gradual addition of atoms from the smaller particles.
31,32
 The smaller 
nanoparticles dissolve and their atoms redeposit onto the larger, because the larger particles have 
a lower surface energy. These newly formed clusters thus result in more aggregation as the 
consequential, strong magnetic dipole-dipole of the clusters encourages the magnetization of its 




neighbor and their eventual magnetic attraction.
23,25
 Surface modifications are indispensable in 
that they stabilize the nanoparticles, thereby reducing these attractive interactions. Surface 
modifications can come in the form of polymeric and inorganic materials. Furthermore, iron 




1.3.2. Gold Nanoparticles 
Gold nanoparticles are chemically inert and highly biocompatible.
34,35
 Connor et al. 
found that 18 nm particles, for example, can be taken up by human leukemia cells with no 
cytotoxic side effect.
34
 Similarly, according to Loo et al., gold nanoshells are nontoxic.
30
  Loo et 
al. found that SKBR2 breast-cancer cells exposed to 3×10
9
 nanoshells/mL for one hour exhibited 
no viability loss compared to control cells.
30
 Moreover, researchers can enhance the 
biocompatibility of gold nanoparticles via attachments of polymeric stabilizers such as PEG.
30
 
Surface coatings, including PEG, define a large part of the bioactivity of the nanoparticle in 
addition to determining cytotoxicity.
30
 These ligands attach through alkanethiolated adsorption to 
the gold surface.
33
 This characteristic of gold allows an assortment of moieties to attach to a gold 
nanoparticle through a thiol-terminus, enabling the nanoparticle to be multifunctional. 
A gold shell covering an iron oxide core provides chemical and biological 
functionalization and long-term stabilization of the core.
35
 Gold, therefore, has been commonly 
used to coat iron oxide nanoparticles, protecting them against oxidation.
17
 Moreover, the gold 
shell provides a platform of functionality for the particle. These surface additions consequently 
enable the particle to be useful for various biomedical applications. For example. cancer-
targeting ligands, such as monoclonal antibodies and peptides, have been conjugated to Au NPs 





Also, surface functionalizations help to further prevent aggregation, 




One common method to coat the iron oxide core with gold (Au) is using the protocol set 
out by Levin et al. (Another being to create an intermediate layer of silica around the iron oxide 
core before forming the gold shell.
37,38
) To begin, monodisperse FexOy nanocrystals are 
functionalized with a coupling agent, (3-aminopropyl)-trimethoxysilane (APTMS), whose silane 
terminus binds to the FexOy surface and its amine-terminus later serves as a binding site for 2 nm 
Au particles.
35
 Once the Au colloid is added, gold salt (AuCl4
-
) can be reduced onto the surface 
to form a continuous gold shell using formaldehyde. The ratio between the concentration of the 
iron salts and the concentration of the gold salt used controls the thickness of the gold shell.
35
 
1.4 Project Description and Goals 
 Our overarching goal for this project is to develop a multi-purpose nanovehicle (shown in 
Figure 7) that targets, images, and with high specificity destroys pancreatic cancer cells. 
 
Figure 7: Schematic of fully functionalized nanovehicle. Components are to scale. 
Working from the core outward, the nanovehicle contains an iron oxide core, which serves as a 
contrast agent for magnetic resonance imaging. A gold shell then encompasses the core to 
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increase the biocompatibility of the nanoparticle within the body. The gold nanoshell also 
enables the attachment of a diverse number of chemical moieties, such as antibodies and 
biocompatibility agents, to the nanovehicle. Harnessing the gold shell as a platform, the surface 
is decorated with polyethylene-glycol (PEG) to enhance the biocompatibility further by 
improving circulation time and stability.
14
 The polymer’s previously discussed properties 




One end of the PEG is thiol-terminated for attachment onto the gold surface, whereas the 
other has a biotin terminus to take advantage of the strong coupling between biotin and avidin, 
which was demonstrated by Goldman et al.
39
 Avidin is a protein with four binding sites, to which 
the targeting and therapeutic agents can attach. The targeting agent, the chimeric human-mouse 
monoclonal antibody (CHO 31.1), is then biotinylated and attached to the binding site. CHO 31.1 
targets the antigen on the tumor pancreatic cancer cell surface: glycoprotein A33.
40
 The presence 
of the targeting ligand, CHO 31.1, enables the nanoparticle to enter the cell through receptor-
mediated endocytosis.
15
 Its presence enhances cellular uptake by cancer cells, thus minimizing 
the dependence on the enhanced permeability and retention effect as well as circumventing the 
accumulation of cytotoxic drugs in healthy tissue.
15
 Furthermore, the attachment of the 
therapeutic agent, a polymer, poly-(D-glutamate, D-lysine) or poly-GL conjugated to large 
quantities of boron-10, reduces concern of nonspecific killing as a result of the short distance of 





irradiated with low energy thermal neutrons and consequently 
decomposes into alpha particles (
4




 This process destroys only the 
tumor cell as the polymer has been taken up by the targeted cancer cell, via CHO 31.1, and the 
15 
 
damage extends only 5–9 μm.41 In total, the specificity of the nanovehicle provided by CHO 
31.1, the short path length of the emitted alpha particles, the increased biocompatibility afforded 
by PEG and the gold shell, as well as the ability to detect and image via the iron oxide core, 
combine to form an ideal alternative to current treatments for pancreatic cancer. 
 My focus is specifically on the iron oxide core-gold shell conjugate. My objectives are to 
optimize the synthesis of the gold-coated iron oxide nanoparticles by determining the optimal 
concentration of APTMS, number of exposures to 2 nm gold nanoparticles, and concentration of 
Gold Enhance
TM
. These particles will be characterized via FT-IR, UV-Vis spectroscopy, 
dynamic light scattering, inductively coupled plasma-optical emission spectroscopy, and 
transmission electron microscopy. 
 Previous methods to form the gold shell resulted in either uncoated iron oxide particles or 
particles that were outside the biological size restraint.
42,43
 I will be synthesizing the iron oxide 





Figure 8: Pathway to form a gold nanoshell around an iron oxide core. 
First, the iron oxide core will be functionalized with (3-aminopropyl)-trimethoxysilane 
(APTMS). The APTMS-functionalized nanoparticles are then seeded with 2 nm gold 
nanoparticles, which covalently interact with the amine-terminus on the APTMS.  Gold 
Enhance
TM
 is a commercially available kit that allows for the reduction of gold ions onto the 
APTMS- and 2 nm Au seeds-functionalized core. Gold Enhance
TM
 was originally used to enlarge 
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particles for better electron microscope observation and has shown promising results in our aim 







For all synthetic and characterization steps, high purity “nanopure” water (nH2O) was 
used (purified to 18.3 MΩ cm using a Barnstead Nanopure Ultrapure Water System). For the 
synthesis of FexOy NPs using the Kang et al. protocol, FeCl2•4H2O (Sigma Aldrich), FeCl3•6H2O 
(Fisher Scientific), HCl (12.1 N), and NaOH (1.5 M) were used. Alternative FexOy NPs were 
purchased from Ferrotec (EMG 304, 4.5% v/v, 10 nm average size). (3-aminopropyl)-
trimethoxysilane (APTMS) (Sigma Aldrich, 97%), 2 nm Au NPs (Ted Pella, Unconjugated Gold 
Colloid, 1.5 × 10
14
 particles/mL), and Gold Enhance
TM
 (Nanoprobes, Gold Enhance
TM
 LM/Blot) 
were used to create the Au shell. α-thiol- and ω-carboxylic acid terminated poly(ethylene glycol) 
(MW = 2,600 Da) was obtained from Polymer Source, Inc. Pure atomic spectroscopy gold 
(PerkinElmer 2% HNO3) and iron (SPEX CentriPrep 100 mg/L 5% HNO3 or 1000 mg/L 2% 
HNO3) standards were used to prepare standard solutions for calibration for inductively coupled 
plasma-optical emission spectrometry (ICP-OES) characterization. High purity HNO3 
(OmniTrace 69–70%) was used to prepare and digest samples for ICP-OES, either alone or used 
to make aqua regia. For preparation, HNO3 was diluted to 2% with nH2O. HCl (ACS grade) and 
HNO3 (ACS grade) were used in a 1:3 ratio to make aqua regia for washing. 
2.2. Instrumentation 
Fourier Transform-Infrared (FT-IR) Spectroscopy 
Infrared spectra were collected to verify presence of APTMS and to confirm APTMS-
stretch fidelity to literature. Spectra were obtained on a PerkinElmer Spectrum One FT-IR 
spectrometer with a PerkinElmer Universal ATR sampling accessory. In final syntheses, a 
Bruker ALPHA FT-IR spectrometer with a platinum ATR platform was used. Data were 
18 
 
collected from 600–4000 cm-1 with 128 scans at a resolution of 4.00 cm-1, on both spectrometers. 
Air was used as the background scan. A sample volume of 2–3 μL was used for each run. To 
increase the signal to noise ratio and in order to use air as a background, FexOy samples were left 
to air dry for 30 minutes to an hour before measurement. 
Ultraviolet-Visible (UV-Vis) Spectroscopy 
UV-Vis spectra were used to determine presence of Au shell, dispersion and relative size 
of FexOy/Au NPs and 2 nm Au seeds. Spectra were also used to analyze supernatants of 
FexOy/Au NPs after functionalization with 2 nm Au NPs and after addition of Gold Enhance
TM
 to 
the NPs. Spectra were obtained using a Varian Cary 500 Scan UV-Visible-NIR 
spectrophotometer. Absorbance data was collected using a 1-cm path length quartz cuvette and 
1/3 or 1/6 dilutions. Settings for obtaining absorption spectra are detailed in Table 1. 









800–175 600 Full 
Table 1: Settings for obtaining absorption spectra 
 
Dynamic Light Scattering (DLS) 
Particle hydrodynamic diameter and polydispersity of solutions of bare, APTMS-
functionalized, and Au-coated FexOy NPs were measured using DLS. Data were taken on a 
Malvern ZetasizerNano 2S running Zetasizer Software 6.0.1. Diameters and polydispersity index 
(PDI) was recorded from the “Size Distribution by Number” report. Samples were sonicated for 
90 seconds with an ultrasonic horn; 400 μL of sonicated sample were mixed with 1 mL nH2O. 
The solution was filtered using a 25 mm syringe filter with a 0.45 μm cellulose acetate 
membrane (VWR International); approximately 1 mL of solution was then put into a four-sided 
19 
 
or two-sided plastic cuvette. The coating material determined the parameter files, which are 

























0.8872 1.330 1.450 0 in water 
Table 2: Settings for dynamic light scattering measurements 
 
Inductively Couple Plasma-Optical Emission Spectroscopy (ICP-OES) 
ICP-OES was used to determine the concentration of the FexOy NPs stock solutions and 
Au-coated FexOy NPs. A PerkinElmer Optima 7000 DV ICP-OES instrument was used for all 
runs. FexOy NPs were digested in high purity aqua regia or high purity 70% HNO3 (OmniTrace) 
overnight; Au NPs and Au-coated FexOy NPs were digested in aqua regia overnight. All digest 
samples were then diluted to 2% HNO3 with nH2O. All samples were diluted with 2% HNO3 to 5 
mL. When digesting the samples with aqua regia, a sample of aqua regia was also diluted and 
included in the set of samples. Samples were introduced at a flow rate of 1.5 mL/min. Emission 
wavelengths of 267.595 nm and 238.204 were used to detect gold and iron, respectively. A 
calibration curve was constructed from serial dilutions with concentrations of 0.01, 0.1, 1, 10, 
100 ppm (or mg/L) of the gold standard and 0.004, 0.04, 0.4, 4, 40 ppm (mg/mL) of the iron 
standard, using 2% HNO3 as a diluent. nH2O was used to dilute iron standard to 2% HNO3, when 
needed. A 2% nitric acid solution diluted from 69–70% was used as the calibration blank. The 





Transmission Electron Microscopy (TEM) 
Morphology and distribution of sizes of bare and gold-coated Ferrotec and Kang NPs 
were examined using a Philips CM 10 transmission electron microscope. Samples were prepared 
by placing 1–2 μL of sonicated sample to copper, Formvar-coated 400 mesh carbon TEM grids. 
Samples were then allowed to air dry. Particle size was measured manually by translating a dot 
on the imaging screen across the diameter of a particle; translation distance was recorded by the 
instrument. There was occasional difficultly in determining size owing to aggregation of 
particles, which masks the dot and inhibits accurate reading. 
2.3. Synthetic Methods 
FexOy Core Synthesis 
Iron oxide nanoparticles (FexOy NPs) were synthesized using a co-precipitation method 
developed by Kang et al., herein referred to as Kang NPs.
46
 FeCl2•4H2O (0.8004 g) and 
FeCl3•6H2O (2.0813 g), which was crushed into powder by mortar and pestle, were dissolved in 
HCl (1 mL, 12.1 N) and nH2O (10 mL, 18.3 MΩ cm). The solution was purged again with 
nitrogen gas for 20 minutes, while stirred with a magnetic stir bar. While purging, the flask was 
sealed with parafilm to prevent reintroduction of oxygen. The bubbling of nitrogen gas through 
the solution protects the oxidation of the magnetite (Fe3O4) and reduces particle size.
23
 The iron 
chloride mixture was then added drop-wise to NaOH solution (100 mL, 1.5 M, previously 
purged for 25 minutes) and stirred vigorously with a magnetic stir bar, while NaOH solution was 
still being purged with N2 gas. The product was isolated overnight using a magnet and the 
supernatant was decanted. The NPs washed three times, each with nH2O (75 mL, 18.3 MΩ, 
previously purged for 20 minutes). Each time the supernatant was pipetted out. The final wash 
was conducted with HCl (200 mL, 0.1 M). Collection while suspended in HCl was a slow 
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process and so centrifugation was used. The iron oxide cores were then resuspended in nH2O. 
The stock solution was then characterized by DLS, FT-IR spectroscopy, UV-Vis spectroscopy, 
and TEM. The concentration was determined using ICP-OES as well was chelation and UV-Vis. 
Au-FexOy NP Synthesis 
The procedure for coating Ferrotec and Kang NPs was adapted from Brinson et al. and 
optimized from previous synthetic procedures.
47,44 
Varying concentrations of FexOy NPs, 
APTMS, and Gold Enhance
TM
 as well as number of exposure of 2 nm Au NPs were used. 
The (3-aminopropyl)-trimethoxysilane (APTMS) functionalization serves as the initial 
step in the Au-FexOy NP synthesis. Table 3 shows the different amounts of FexOy and APTMS 
used. Total volume was achieved through addition of nH2O. 









1.620 5.000 5.000 50 
100 
Table 3: Amounts used for APTMS-functionalization 
 
 FexOy NPs suspended in nH2O were sonicated for 5.5 minutes. APTMS was then added 
to the FexOy NPs solution, diluted to 1.620 mL, and put on the wrist-action shaker for 30 
minutes. The NPs were collected over a magnet and the supernatant was removed once the 
solution was clear. The NPs then were redispersed in 5 mL nH2O. Two additional collections and 
redispersions were performed. The success of APTMS-functionalization was then checked with 
FT-IR spectroscopy. 
 The amine-terminus on the APTMS promotes the attachment of 2 nm Au NPs through 
the NH2-Au covalent interaction. The 2 nm Au NPs then encourages the nucleation of reduced 
Au
3+
 onto the nanoparticle surface. 
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 To attach the 2 nm Au NPs, the APTMS-functionalized FexOy NPs were first sonicated 
for 90 seconds and an aliquot removed. The amount of FexOy as well as 2 nm Au NPs, total 
volume, and washes are listed in Table 4. The aliquot was placed in a new, foil-covered vial; the 
vial serves to protect the photosensitive Au NPs. The APTMS-functionalized FexOy NPs and 2 
nm Au NPs (seeds) were diluted to 15.0 mL, and then put on the wrist-action shaker for 24 
hours. The product was collected by a magnet and the supernatant was decanted once the 
solution was clear. Supernatants were then saved and stored in foil-covered vials to confirm 
success of washes using UV-Vis spectroscopy. Here, the number of exposures is parameterized. 
For one exposure, two additional collections and redispersions were performed (see Table 4 for 
specific values). However, for two exposures, the procedure for the first exposure is repeated on 










nH2O for final 
redispersion (mL) 
Amounts 0.245 5.0 15.0 5.000 0.500 
Table 4: Amounts used for 2 nm Au NPs addition 
 
 The final process entails adding Gold Enhance
TM
 (GE) to the seeded FexOy NPs. Equal 
amounts of each of the four GE components (A, B, C, and D) were used in this synthesis.  The 
amount of FexOy NPs, volume of washes, and redispersion as well as the sum of the GE volume 





of GE (mL) 
nH2O for 
washes (mL) 




5.000 2.000 1.000 
1.400 
Table 5: Amounts used for addition of Gold Enhance
TM 
 
To begin, components A and B are mixed in an Eppendorf tube. After vortexing, the 
mixture was covered and sat for 10 minutes. During that time, the seeded FexOy NPs were 
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sonicated for 90 seconds and an aliquot was added to new, foil-covered vial. After the 10 
minutes, C and D were added to the Eppendorf tube and vortexed. The entire volume was then 
added to the seeded FexOy NPs. The vial was placed on the wrist-action shaker for 20 minutes 
then placed by a magnet to collect overnight. Once the product had collected, the supernatant 
was collected and the product was redispersed in nH2O. The supernatant was collected two 
additional times, each with the product being redispersed in nH2O. DLS and UV-Vis 
spectroscopy, and TEM were used to characterize the Au-coated FexOy NPs. 
Tests for Limit of Quantification of Au NPs 
 500 μL Au NPs from CR3093a were digested in aqua regia, which was made with high 
purity HCl and HNO3. Sample was run using 300 μL of aqua regia. The concentration of gold 
found in aqua regia sample was subtracted from concentration of Au NP samples. 
Acid Digestion of Au NPs 
 100 μL of Au NPs from CR3093a were digested in 125 μL of either aqua regia or 70% 
HNO3 to test if HNO3 would digest Au. Both acids were high purity. Volumes of 100 μL of Au 
NPs were digested in 125 μL of either aqua regia, as a reference, and 70% HNO3. Samples were 
centrifuged at 13,000 RPMs (16,060×g) for 40 minutes at 21°C. 160 μL of the supernatants were 
collected and diluted to 2% HNO3 in pre-washed falcon 15 mL tube. 
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3. Results and Discussion 
 My specific focus for our nanovehicle is the superparamagnetic iron oxide (FexOy) core, 
which provides contrast in MRI, and the gold shell, which serves as a platform for attaching the 
targeting and therapeutic moieties. The nanovehicle is shown in Figure 9, complete with 




 The early syntheses did not have a standardized protocol. Alterations to parameters were 
made in terms of volume of reagent (i.e. μL or mL), rather than in proportion to FexOy 
nanoparticles (e.g. μL/mg FexOy NPs or mL/mg FexOy NPs). As a result, all syntheses completed 
cannot easily be compared directly; only those either within the same run or after the 
standardized protocol can be compared. For testing of parameters, FexOy NPs made from the 
Kang et al. protocol were used for examination of APTMS concentration and purchased FexOy 
NPs from Ferrotec were used for examination of number of 2 nm Au NPs exposures and of Gold 
Enhance
TM
 concentration.  
3.1. Synthesis and Characterization of FexOy Nanoparticles 
The nanovehicle in its entirety must be within the 10–100 nm biological size 
constraint.
15,17
 The length of the antibody is 10 nm (Drew Webb, personal communication) and 
Figure 9: Schematic of fully-functionalized, multi-purpose nanovehicle to scale. Picture adapted from Lisa Jacobs '12 
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avidin, which serves as the docking site for the targeting and therapeutic agents, has a length of 5 
nm with an expected hydrodynamic diameter of 6–9 nm.48 Previous work also found that the 
hydrodynamic diameter of HS-PEG-biotin was 16 ± 8 nm, where the diameter depends on 
whether the PEG chains are compressed and located close to the NP surface or are extended 
away from the surface.
48
 The Au-coated FexOy cores, therefore, should be approximately 10–75 
nm. In order to be superparamagnetic, the FexOy nanoparticles are constrained to 6–15 nm 
otherwise they will be ferromagnetic.
26
 For the FexOy core, two kinds of magnetite were used: 
Kang nanoparticles and Ferrotec nanoparticles. Both sources are characterized through DLS, 
UV-Vis spectroscopy, FT-IR, and TEM. Stock solutions were made by diluting either the 
synthesized or the purchased FexOy NPs in nH2O; ICP-OES was used to determine the 
concentration of iron in the stock solution, from which all aliquots for syntheses were taken.  
Kang Nanoparticles 
 Kang NPs were synthesized using a co-precipitation method, outlined by Kang et al.
46
 
This synthesis yielded spherical, black magnetite (Fe3O4) nanoparticles. The concentration of the 
colloidal FexOy NPs dispersed in nH2O, now the stock solution, was found using ICP-OES, as 
detailed in Section 2.3. This protocol was used because of its simplicity and the expected average 
size of 8.5 ± 1.3 nm.
46
 With this core diameter, the fully-functionalized nanoparticle will be 
between 10–100 nm. The Kang NPs were characterized using FT-IR, UV-Vis spectroscopy, 
DLS, and TEM. 
 The FT-IR spectrum shown in Figure 10 serves as a basis for comparison when the bare 
Kang NPs are APTMS-functionalized. The bare Kang NPs have a strong, broad band at 
approximately 3375 cm
-1
 and another, smaller peak at approximately 1630 cm
-1 
as a result of the 
presence of hydroxyl groups on the NP’s surface.49,50 The characteristic vibration of the Fe-O 
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bond in Fe3O4 NPs is at 580 cm
-1
, which is out of range for the spectrum.
49,50
 However, the large 
band forming near 600 cm
-1
 is evidence of this peak. This spectrum agrees with characterizations 
done by Gupta et al., Kohler et al., and Petcharoen et al. and suggests successful creation of 
Kang NPs.
27, 49,50  
 
Figure 10: FT-IR spectrum of dried bare Kang NPs, 128. 
  
UV-Vis spectroscopy is used primarily as evidence of Au shell formation; UV-Vis 
characterization also provides indirect information about the thickness of shell, shape of the 
nanoparticle, and extent of aggregation. Analysis of Au-coated FexOy NPs spectra will be 
discussed further in Section 3.2. Figure 11 shows the UV-Vis spectrum of bare Kang NPs, which 
possess an increasing absorbance as you move into the UV region. This absorbance matches 
what is expected from the literature.
51
 The spectrum, overall, can serve as a starting point for 




Figure 11: UV-Vis spectrum of bare Kang NPs in nH2O 
 
Characterization through TEM provides the distributions of size and morphology of the 
nanoparticles. Figure 12 shows an electron micrograph of the synthesized Kang NPs. The 
nanorod, located off-center in the micrograph, clearly illustrates the presence of γ-Fe2O3; Kang et 
al. note that maghemite (γ-Fe2O3) nanorods can be formed through direct oxidation of Fe3O4.
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To prevent γ-Fe2O3 formation, solutions were nitrogen purged for longer durations in later 
syntheses. Size was not recorded for the samples in the pictured micrograph.  
 
Figure 12: Transmission electron micrograph of bare Kang NPs. Courtesy of Eugenia White ‘13 
 
DLS was used to analyze the size and size distribution of bare Kang NPs. More 
specifically, the hydrodynamic diameter and polydispersity index (PDI) or relative size 
distribution was found through DLS. PDI is on a scale from 0 to 1, with 1 being highly 
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polydispersed. Figure 13 shows a DLS curve with a PDI of 0.12. This curve illustrates how an 
ideal size distribution looks; there are no shoulders or peaks at other sizes. PDI values of less 
than 0.3 are considered acceptable.  
 
Figure 13: DLS curve with a peak size of approximately 35 nm and a PDI of 0.12 
 
As shown in Table 6, the Kang NPs are larger than the expected value, despite sonication 
and filtration of particles larger than 450 nm. The first synthesis yielded NPs of 39 ± 4 nm and 
the second synthesis yielded NPs of about 16 nm. The first synthesis may have generated larger 
nanoparticles because the reaction was not nitrogen-purged for long enough, as indicated by the 
presence of maghemite (γ-Fe2O3) shown in the Figure 12. There was no evidence of γ-Fe2O3 NPs 






Bare Kang NPs 
(Synthesis 1) 
35.8 0.25 
Bare Kang NPs 
(Synthesis 1) 
41.4 0.28 
Bare Kang NPs 
(Synthesis 2) 
15.7 0.23 




Exacerbating the problem of sizes, the nanoparticles aggregate over time as shown in 
Table 7. The hydrodynamic diameter increases from 39 ± 4 nm to approximately 69 nm, likely as 
a result of van der Waals forces and Ostwald ripening.
23,25,31,32 
To avoid aggregation, the FexOy 







Bare Kang NPs 
(Synthesis 1) 
4/8/12 35.8 0.25 
Bare Kang NPs 
(Synthesis 1) 
4/8/12 41.4 0.28 
Bare Kang NPs 
(Synthesis 1) 
6/4/12 69.1 0.17 
Table 7: DLS measurements of same bare Kang NPs suspended in nH2O on different days 
  
Ferrotec Nanoparticles 
 Ferrotec NPs are commercially available FexOy NPs with an expected diameter of 10 nm 
and spherical morphology. We suspect these NPs are coated with a stabilizing surfactant to 
prevent particle agglomeration. This theory is supported by the FT-IR spectrum of the NPs and 
will be discussed below. Before characterization, the Ferrotec NPs are originally dispersed in 
deionized water and are later diluted in nH2O. NPs were similarly characterized by FT-IR, UV-
Vis spectroscopy, and DLS. 
FT-IR characterization was again used to provide a basis on which we can compare the 
APTMS-functionalized FT-IR spectrum. Figure 14 shows the FT-IR spectrum for bare Ferrotec 
NPs. Similar to the Kang NPs and literature, the Ferrotec NPs spectrum shows a strong, broad 
band at 3400 cm
-1
 and another, smaller peak at 1600 cm
-1
, indicative of the hydroxyl groups on 
the nanoparticle’s surface.49,50 The spectrum also shows evidence of the characteristic Fe-O 
bond, expected at 580 cm
-1




 We attribute the 









Figure 14: FT-IR spectrum of bare Ferrotec NPs, 128. 
 UV-Vis absorption spectrum of bare Ferrotec NPs was again taken for reference and is 
shown in Figure 15. The Ferrotec NPs absorbance spectrum is nearly identical to that of the 
Kang NPs. The NPs exhibit a gradual increase in absorbance from 800 to 400 nm, with no 
distinct peaks.  
 
Figure 15: UV-Vis absorption spectrum of bare Ferrotec NPs suspended in nH2O 
 
Ferrotec NP characterization through TEM confirms the spherical morphology of the 
FexOy NPs, as shown in Figure 16. The micrograph also gives an overview of the size of the 




Figure 16: TEM image of bare Ferrotec NPs. Courtesy of Alice Liao '15 
DLS was again used to determine the hydrodynamic diameter and distribution of size of 
the FexOy NPs. Newly purchased Ferrotec NPs have an average hydrodynamic diameter of 17.6 
nm, as listed in Table 8. Its PDI value of 0.16 indicates that the NPs are relatively monodisperse. 
The average hydrodynamic diameter is larger than the true value that would be seen by TEM, as 
it includes the solvated shell in the calculation. The hydrodynamic diameter is within the 10 to 
25 nm range seen by TEM, thereby correlating to the observations seen by TEM. Moreover, the 
NPs, as seen in the TEM micrograph in Figure 16, are largely monodisperse, which the DLS PDI 
value confirms. It is important that the Ferrotec NPs be replaced in regular intervals as 
aggregation is also a concern for Ferrotec NPs. The previous source of Ferrotec NPs had been in 
use for at least a year and a half and by the end of that time the NPs had agglomerated to a 





Ferrotec NPs 17.6 0.16 




Initial syntheses used Kang NPs; considering Ferrotec NPs more reliably had smaller 
initial diameters, later syntheses instead used the commercially available FexOy NPs.   
3.2. Functionalization of FexOy Nanoparticles with APTMS 
 Functionalization of the FexOy NPs with (3-aminopropyl)-
trimethoxysilane or APTMS serves as the first step in the Au shell 
formation. The structure of the compound is shown in Figure 17. The 
silicon atom is chemisorbed to the iron oxide surface following a 
condensation reaction of its methoxy groups with the hydroxyl groups on the NP’s surface. The 
nanoparticle now possesses exposed amine groups, provided by the amine-terminus of APTMS. 
The presence of the amine groups is important as, similar to thiols, the amine has an affinity for 
gold by forming a weak covalent bond. The 2 nm Au NPs can therefore be secured to the 
nanoparticle’s surface and provide a site for nucleation of gold ions to form the gold shell. The 
success of the APTMS-functionalization was monitored by FT-IR characterization. 
 A comparison of free APTMS (black spectrum), bare FexOy NPs (red spectrum), and 
functionalized FexOy NPs (blue spectrum) is shown in Figure 18. On the functionalized FexOy 
NPs spectrum shown in blue, two key peaks are present that indicate successful 
functionalization: 2912 cm
-1
 and 2848 cm
-1
. These two peaks correspond to the C-H symmetric 
and antisymmetric stretches of the methylene on the propyl chain on APTMS (shown in black) at 
2928 cm
-1




 The strong band at approximately 1100 cm
-1
 is 
indicative of the Si-O bonding to the nanoparticle surface, as discussed by Kohler et al.
50
 The 
bands for the APTMS-functionalized FexOy NPs are found at lower frequencies as a result of the 
attachment to the nanoparticle. The amount of shift of the band overall depends on the metal 
ion’s electronegativity, size, and number of valence electrons.53 
Figure 17: Chemical 




Figure 18: Comparison of FT-IR spectra to determine successful functionalization of APTMS 
 
 APTMS immobilizes 2 nm Au NPs, which serve as nucleation sites for growth of the Au 
shell, onto the FexOy NP surface.
54
 An increase in nucleation sites theoretically yields more Au 
shell coverage, which in turn prevents aggregation of the NPs and decreases the sample size.
54
 
Therefore, increasing amounts of APTMS were used to determine its effect on the formation of 
the gold shell. The exploration began with an increase in the amount of APTMS used for Kang 
syntheses from 20 to 100 μL APTMS/mg FexOy NPs, keeping all other parameters the same. The 
samples were compared using primarily DLS and UV-Vis spectroscopy.  
 When the concentration of APTMS was increased and all other parameters remained 
constant, the hydrodynamic diameter decreased as shown in Table 9. The sample set with 16.3 
mL GE/mg decreased in diameter from 217 nm to 206.7 nm with the increase in APTMS. 
Similarly, the sample set with 9.8 mL GE/mg decreased from 218.4 to 141.7 nm. When the 
amount of APTMS was further increased to 372 μL APTMS/mg FexOy, the hydrodynamic 
diameter became 128.4 nm with a PDI of 0.18. This overall trend indicates that an increase in the 












20 μL/mg FexOy 16.3 mL/mg FexOy 217 0.16 
100 μL/mg FexOy 16.3 mL/mg FexOy 206.7 0.19 
20 μL/mg FexOy 9.8 mL/mg FexOy 218.4 0.21 
100 μL/mg FexOy 9.8 mL/mg FexOy 141.7 0.29 
Table 9: DLS measurements for the increase of APTMS   
 
UV-Vis spectroscopy serves as an indirect analysis of the gold shell formation and 
thickness as well as shape and aggregation of the sample. Gold exhibits a specific and intense 
absorption band in UV-Vis as a result of a phenomenon called surface plasmon resonance.
55
 The 
features of Au NPs’ spectral band depends on the size, shape, and aggregation of the 
nanoparticles.
55,56




The plasmon band position and bandwidth, which is measured by the full width at half of 
the maximum absorbance, will be the primary tools in UV-Vis characterization. Optimal Au-
coated FexOy NPs have full Au-shell coverage, a thin shell, and minimal aggregation. To 
determine full coverage, the surface plasmon (SP) band of the Au-coated FexOy NPs are 
compared to that of monometallic Au NPs, which have a SP band at 520.
33
 Increases in Au shell 
thickness yield a red-shift in the peak, or a lengthening of the peak wavelength.
35
 The proximity 
of the peak wavelengths to 520 nm is therefore analyzed. The bandwidth of the peak lends 
information about the size distribution and aggregation of the sample, where a smaller bandwidth 
indicates a smaller distribution in size and less aggregation. 
Figure 19a compares the absorption spectra of samples of 20 versus 100 μL APTMS/mg 
and 16.3 μL GE/mg, whereas Figure 19b compares samples of 20 versus 100 μL APTMS/mg 
and 9.8 μL GE/mg. The particles with a smaller hydrodynamic diameter are expected to be closer 
to 520 nm than those with a larger diameter; however, Figure 19a shows a shift from 547 nm to 
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551 nm as APTMS is increased. The bandwidth, measured by the full width at half of the 
maximum absorbance (FWHM), in Figure 19a decreases from 71 nm to 67 nm. In terms of 
FWHM, 100 μL APTMS/mg is a more promising concentration, but in terms of peak position 
the opposite is implied. Meanwhile, Figure 19b shows the expected blue-shift from 555 nm to 
545 nm and a decrease of FWHM from 76 nm to 65 nm. In this sample set, both the position of 
the absorbance peak and the FWHM indicate that 100 μL APTMS/mg yielded a more promising 
sample than 20 μL APTMS/mg.  
 
Figure 19: Comparison of UV-Vis absorption spectrum for increase of APTMS. a) Synthesis uses 16.3 mL GE/mg 






As seen in the analysis of Figure 19a, data from UV-Vis characterization can be 
conflicting. This likely arises because UV-Vis spectroscopy is an indirect method of assessing 
the nanoparticles. TEM characterization is needed to more confidently interpret findings. 
A synthesis increasing the APTMS to 372 μL APTMS/mg Kang confirmed this overall 
trend. The synthesis yielded a hydrodynamic diameter of 128.4 and a PDI 0.18. Figure 20 shows 
the absorption spectrum of this synthesis as well that of the best particles from the previous 
syntheses. The spectra confirm the decrease in size by showing a blue shift from 545 nm to 538 
nm. Also, the 372 μL APTMS/mg has a smaller distribution in size as indicated by its lower PDI 
(0.18 versus 0.29) and its narrower bandwidth (52 nm versus 65 nm). 
 
Figure 20: UV-Vis absorption spectrum comparing 327 μL APTMS/mg and 100 μL APTMS/mg. Syntheses used 
different concentrations of GE. The absolute absorbance for the 372 μL APTMS/mg sample is lower because the 
concentration of FexOy for this sample was smaller than the previous samples. 
 
As the data show, there is a decrease in size with an increase in APTMS, thus larger 
concentrations of APTMS should be tested. As was discovered by Ashayer et al., more coverage 
of APTMS of the NP’s surface enables the surface saturation with 2 nm Au NPs. As the seeds 
provide nucleation sites for the growth of the Au shell, more APTMS is optimal.
54
 However, an 
increase above the optimum concentration results in the precipitation of the NPs.
54
 To find the 
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optimum concentration, an amine assays may be helpful in determining at what concentration the 
APTMS would saturate the NP surface, as was done by a previous student.
44
  
 During the APTMS-functionalization step, iron oxide nanoparticles adhered to the sides 
of the vial in later syntheses as shown in Figure 21. We originally thought the NPs were 
interacting with the deprotonated hydroxyl groups on the glass vials. Therefore, a number of 
pretreatment methods were used to try to combat this problem by coating the glass surface. The 
first pretreatment method involved soaking the vial in 2% HNO3 overnight. After this was 
unsuccessful, vials were then washed in the specified concentration of APTMS dilute in nH2O 
overnight. Final attempts were made using 1%, 5%, and eventually 10% w/v of polyethylenimine 
to wash the vials for 30 minutes. As none of these methods were successful, the specific cause 
for the interaction between the vial and FexOy NPs could not be determined. 
 
Figure 21: Example of APTMS-functionalization resulting in FexOy NPs sticking to vial 
 
3.3. Seeding of FexOy Nanoparticles with 2 nm Gold Nanoparticles 
 After APTMS-functionalization, 2 nm Au NPs are then added to the FexOy nanoparticle. 
The resulting small Au NPs bound to the surface of the FexOy nanoparticle serves as a “seed” or 
nucleation site for the formation of the Au shell. More specifically, the seeding of 2 nm Au NPs 
onto the FexOy surface promotes the reduction of Au
3+
 ions to Au
0
. This reduction and adsorption 
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creates islands of Au.
47
 With continued reduction and deposition of gold, the islands then 
coalesce to form a shell around the nanoparticle.
47
  
 The seeded nanoparticles were not characterized after the seed addition as no discernible 
change occurred in UV-Vis spectroscopy. Early attempts were made to compare the 2 nm Au 
seeds found in the supernatant through UV-Vis spectroscopy, however, results were inconsistent. 
Additionally, the 2 nm addition would be too small to discern on DLS and TEM. 
 Initially, one exposure of 122.7 mL of 2 nm Au NPs/mg FexOy NPs was used. A decrease 
in the amount of 2 nm Au NPs was tested, as this was a large volume for a small amount of 
FexOy and the seeds are expensive. Syntheses continued to be successful despite the decrease to 
20.4 mL of 2 nm Au NPs/mg FexOy. 
Figure 22 illustrates the successful formation of Au shells despite a decrease in single 
exposure volume. Figure 22a shows the spectra of two samples with the same concentration of 
APTMS and number of exposures, but different amounts of Gold Enhance
TM
. As discussed in 
Section 3.2, a spectral band between 500 and 700 nm indicates the presence of gold in the 
samples. Both samples in Figure 22a have a peak in this region; the sample with 8.2 mL GE/mg 
has a peak at 590 nm and 11.5 mL GE/mg at 623 nm. Both samples have large bandwidths, with 
a FWHM of 177 nm and 223 nm, respectively. In conjunction with the red-shifted peaks and 
large bandwidths, the overt similarities of the samples’ absorbances to that of bare FexOy, 
intentionally emphasized in Figure 22b, indicate that the particles are likely not fully coated or 
that many particles are left uncoated. Multiple exposures were then tested to determine their 





Figure 22: UV-Vis absorption spectra of syntheses using 1 exposure to 2 nm Au NPs. Amounts of Gold Enhance
TM
 
listed. a) Spectra shown in range 800–400 nm. b) Sample spectra and bare FexOy NPs spectrum shown in range 800–
200 nm to explicitly illustrate similarities 
 
Figure 23 illustrates that the increase in number of exposures results in smaller 
nanoparticles, as shown by its blue-shift to 548 nm from 670 nm for 8.2 mL GE/mg samples and 
552 nm from 651 nm for 11.5 mL GE/mg samples. Additionally, the narrower bandwidths (177 
nm to 88 nm and 223 nm to 74 nm, respectively) illustrate that the 2 exposure samples are more 
promising and that there is less dispersion in their sample size than the 1 exposure samples’. 






Figure 23: UV-Vis absorption spectra comparing number of exposures 
 
The hydrodynamic diameters shown in Table 10 indicate that the addition of a second 
exposure drastically decreased the size of the Au-coated FexOy NP. For the 8.2 mL GE/mg 
samples, the second exposure resulted in a hydrodynamic diameter decrease from 172.6 nm to 
70.54 nm. Similarly, the 11.5 mL GE/mg samples saw a decrease from 126.7 nm to 43.65 nm. 
To confirm this trend, eight syntheses were run. All syntheses used 75 μL APTMS/mg Ferrotec 
and 8.2 mL GE/mg Ferrotec. The four samples with one exposure yielded a hydrodynamic 
diameter of 142 ± 21 nm, whereas the other four syntheses with two exposures yielded NPs with 
60 ± 22 nm hydrodynamic diameter.  
Samples 




1 exposure, 8.2 172.6 0.172 
1 exposure, 11.5 126.7 0.151 
2 exposures, 8.2 70.54 0.133 
2 exposures, 11.5 43.65 0.193 
Table 10: DLS measurements of variable exposures and GE on Ferrotec samples suspended in nH2O 
 
 The TEM image in Figure 24 substantiates the decrease in diameter as a result of two 
exposures. Figure 24 shows uncoated FexOy NPs alongside Au-coated FexOy NPs, which appear 
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black in the micrograph in comparison to the bare FexOy NPs because gold is more electron 
dense than iron. 
 
Figure 24: TEM image showing Au-FexOy from 2 exposures and 11.5 mL GE/mg. Hydrodynamic diameter was 20 
nm. Courtesy of Alice Liao ‘15 
 
Goon et al. found that a dense layer of 2 nm Au NPs on the FexOy surface was crucial in 
ensuring that all FexOy NPs are Au-coated.
57
 Furthermore, they found that the saturation of Au 
seeds on the NP surface encouraged a more uniform distribution of Au deposition for the 
formation of the Au shell.
57
 The effect of three exposures therefore should be investigated in the 
future. The effects of a higher concentration of APTMS in conjunction with multiple exposures 
should also be explored, considering the amine-terminus on APTMS promotes Au seed 
attachment. 
3.4. Formation of Gold Shell 
 The final step of the Au-FexOy NP synthesis involves the reduction of gold cations to 
from the gold shell. To do so Gold Enhance
TM
, a commercially available kit, is used. The product 
contains four containers labeled A-D. Solution A is the enhancer and contains Au
3+
 ions, as 
evident by being the only yellow solution as well as the only colored solution. B is the activator, 
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which contains a gold stabilizing agent to control reactivity, C is the initiator, and D is the buffer. 
The precise identities of the solutions are unknown because of propriety confidentiality. 
Originally, the kit was used to grow a gold nanoshell around gold nanoparticles to enhance 
visibility for light microscopy. Previously, attempts at gold shell formation on FexOy NPs were 
done on TEM grids.
44
  
 To ensure that the gold cations were depositing around the seeded FexOy NPs and not 
around free 2 nm Au NPs, tests were run in the absence of FexOy NPs and characterized with 
UV-Vis spectroscopy. The standard seeding and addition of Gold Enhance
TM
 was followed 
exactly, except in the absence of FexOy NPs and APTMS. Purification was done through 
centrifugation at one run of 30 minutes at 12,000 RPMs (14,825×g) and at 10 °C, then a second 
run of 30 minutes at 13,000 RPMs (16,060×g) at 10 °C. The same procedure was followed to 
prepare an aliquot of 2 nm Au NPs. UV-Vis spectroscopy was used to characterize and yielded 
the absorption spectra in Figure 25. The spectra show a peak at 564 nm for the seed and Gold 
Enhance
TM
 (GE) mixture and no peak for the free 2 nm Au NPs between 800–400 nm. There is a 
peak for free 2 nm Au NPs at 187 nm, which is consistent with the literature.
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 This peak was not 
of concern as it was not in the region of interest. The peak arising from the 2 nm Au NP and 
Gold Enhance
TM
 combination, however, is very similar to those seen in Au-FexOy NPs. 
Therefore, the synthesis was repeated and bare FexOy NPs were added to test if the seeds/GE 
would be trapped among the FexOy NPs when collected by magnet. If the NPs were trapped, this 
would indicate that the peaks that were thought to indicate Au-coated FexOy NPs could be the 




Figure 25: UV-Vis absorption of 2 nm Au NP and Gold Enhance synthesis and free 2 nm Au NPs 
 
 The FexOy NPs and seed/GE solution were mixed and collected, by placing the sample 
adjacent to a magnet. After the first iteration of collection, an aliquot of sample was set aside to 
be characterized with UV-Vis spectroscopy and the supernatant was saved. Similarly, the 
supernatant from the second wash was saved. The four solutions were characterized; their 
absorption spectra are shown in Figure 26. The comparison of spectra shows that the successive 
collections by the magnet did not result in seed/GE particles being trapped among FexOy NPs. 
The seed/GE particles are clearly in the supernatant, which is most evident by the peak at 526 nm 




Figure 26: UV-Vis absorption spectra of seed/GE peak test 
 
 The best syntheses to date use 75 μL APTMS/mg Ferrotec NPs and employ 2 exposures 
of 20.4 mL of 2 nm Au NPs/mg. However, the results from varying the amount of Gold 
Enhance
TM
 do not follow a clear trend. Table 11 lists the hydrodynamic diameters for averaged 
samples with the listed number of exposures and amount of Gold Enhance
TM
. Syntheses used 75 
μL APTMS/mg. For 1 exposure, less GE is optimal, whereas, for 2 exposures, more is desired. 
Syntheses with the same concentrations must continue to be repeated in the future to determine 
the effects of Gold Enhance
TM
. Kang samples with varying amounts of Gold Enhance
TM
 are not 















4.9 118 ± 23 
8.2 142 ± 21 
11.5 132 ± 7 
2 
4.9 51 ± 45 
8.2 60 ± 22 
11.5 32 ± 16 
Table 11: DLS measurements of averaged Au-FexOy NPs. 8.2 mL GE/mg samples are averaged from 4 samples; the 




 Regardless of the concentration of Gold Enhance
TM
, number of exposures of 2 nm Au 
NPs, and concentration of APTMS, syntheses do not coat all iron oxide nanoparticles as shown 
through TEM characterization. See Figure 24 and Figure 27 for examples. Both images show 
clusters of FexOy NPs left uncoated. The NPs must be coated with gold in order to be 
functionalized by the targeting and therapeutic agents, and thereby used as a drug delivery 
system. The next section explores acid digestion as a method to remove uncoated FexOy NPs. 
 
Figure 27: Representative TEM micrograph of Au-coated and uncoated FexOy NPs. NPs in this micrograph were 
not measured; therefore no scale bar is included. 
 
3.5. Digestion of Uncoated FexOy Nanoparticles 
 To rid the sample of the uncoated NPs, acid digestion tests were done to determine at 
what percent of HNO3 the uncoated NPs will digest while the Au-coated NPs remain untouched. 
To start, samples with volumes of 5, 10, 50 and 100 μL of Au NPs in 3 mL total volume were 
run to determine approximate limit of quantification. To determine the concentration of the 
samples, a calibration curve must be constructed from the gold standards. The Appendix details 
how the calibration curve and curve-adjusted concentrations were calculated. The calibration 
curve for this run is shown in Figure 28. The linear regression value, represented as R
2
, indicates 
whether or not the data points are highly correlated. Calibration curves with an R
2
 value equal to 
or close to 1 are optimal. Additionally, visual proximity of a data point to the linear fit indicates 
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that a standard is close to or at its expected concentration. The calibration curve in Figure 28 
shows that the standards have high fidelity. 
  
Figure 28: Calibration curve for Au samples digested in A.R. 
 
Table 12 lists the curve-adjusted concentrations in mg/L (ppm) for each sample. The 
concentrations decrease very nearly proportionally to the volume of Au NPs. This signifies that 
the ICP was able to detect the 5 μL samples; if it had not, the concentration would be 
significantly lower than the proportional decrease. Therefore, samples of 0.254 mg/L or 3×10
-4
 
mg/mL can be run and quantified. 
Amount of Au (μL ) 
Curved Adjusted 
Concentration (mg/L) 
100 in 3 mL 5.968 
50 in 3 mL 2.976 
10 in 3 mL 0.552 
5 in 3 mL 0.254 
Table 12: Au concentrations for limit of detection calculation determined from ICP run. Samples were digested with 
300 μL of A.R. and diluted to 3 mL with a combination of nH2O and 2% HNO3 
 
 The first run of the digestion test was to determine the concentration of the Au stock 
solution using aqua regia (A.R.). Aqua regia fully digests Au NPs and the resulting concentration 
should therefore be the true concentration of the stock solution. In parallel, the run tested 
whether or not 70% HNO3 would also digest Au NPs.  
 Figure 29 shows the calibration curve for this run. The calibration curve indicates that the 
standards are, on the whole, highly correlated. The lower concentration standards (1 mg/mL, or 
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0.001 mg/mL and below) have small deviations from the curve; however, they are minor when 
compared to the overall regression and to the concentration of the sample. 
  
Figure 29: Calibration curve for gold samples digested in A.R. and 70% HNO3 
 
The results of this run are converted to mg/mL and are shown in Table 13. The 
calculation of the sample digested in A.R. is the concentration of the stock solution. The 
calculation of the sample digested in 70% HNO3 shows a gold concentration of 0.12 ± 0.02 
mg/mL. This indicates that 70% HNO3 digests Au NPs, as the concentration is not negative nor 
below 3×10
-4
 mg/mL. This also indicates that 70% HNO3 does not digest Au NPs to the extent of 
aqua regia; 70% HNO3 digests approximately 85% of the total Au NPs. The next step was to 
investigate how low the concentration of HNO3 must be for the acid to no longer digest Au NPs. 
A.R.-digested Au NPs were used as a reference for concentration. 
Sample 
Concentration in A.R. 
(mg/mL) 
Concentration in 70% 
HNO3 (mg/mL) 
Au NPs 0.142 ± 0.002 0.12 ± 0.02 
Table 13: Curve-adjusted concentrations for Au NPs in aqua regia and in 70% HNO3. Concentrations are average of 
3 samples 
 
 Au NPs were digested in aqua regia, 70% HNO3, 35% HNO3, and 7% HNO3. Digested 
samples were spun down so that only digested NPs would be included; 160 μL of supernatant 
was used. The calibration curve is shown in Figure 30. The data points are highly correlated for 
concentrations higher than 0.001 mg/mL. The curve-adjusted concentrations are listed in the 
Table 14. As shown in the table, 70% and 35% HNO3 digest Au NPs. 7% HNO3 either does not 
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digest Au NPs or the digested concentration is too low for detection. The gold concentration was 
calculated to be negative (-0.036 ± 0.004), which is not possible as there cannot be less than 0 
mg/mL of Au NPs in the sample. Therefore, intermediate concentrations between 35% and 7% 
HNO3 should be run to test whether there is a concentration higher than 7% that will no longer 
digest gold. A concentration of higher than 7% is more desirable because it will be more efficient 
in digesting FexOy NPs. 
  
Figure 30: Calibration curve for gold samples digest in A.R. 70%, 35%, 7% of HNO3 
 
Acid Used Concentration (mg/mL) 
Aqua Regia 1.41 ± 0.09 
70% HNO3 1.26 ± 0.07 
35% HNO3 0.71 ± 0.04 
7% HNO3 -0.036 ± 0.004 
Table 14: Curve-adjusted concentrations of acid digested Au NPs. Concentrations are an average of 2 samples 
 
Samples digested in intermediate concentrations of 25.1% and 15.1% HNO3 were run 
alongside samples digested in aqua regia and 70% HNO3, which were used for reference. The 
calibration curve is shown in Figure 31. The data points for this run are not as correlated as the 
previous runs as apparent by the R
2
 value and the visual analysis of the curves. The 
concentrations are listed in Table 15. The concentrations are not wholly accurate, as seen by the 
comparison between the concentration of the aqua regia-digested Au NPs in this run and in 
previous runs. However, at this stage, this test is a more qualitative exploration of if there is 
digestion at specific concentrations of HNO3. The lowest concentration run, 15.1% HNO3, yields 
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a gold concentration of higher than the quantifiable limit (0.55 ± 0.05 mg/mL versus 3×10
-4
 
mg/mL). This indicates that 15.1% HNO3, to some extent, digests Au NPs. Therefore, the 
concentration at which there is no appreciable digestion of Au NPs in HNO3 is between 15.1% 
and 7% HNO3. Future experiments should be run to determine a more precise concentration as 
well as if this concentration, or concentration range, of HNO3 will digest FexOy NPs. 
  
Figure 31: Calibration curve for gold samples digested in A.R., 70%, 25.2%, and 15.1% of HNO3 
 
Acid Used Concentration (mg/mL) 
Aqua Regia 1.57 ± 0.04 
70% HNO3 0.5 ± 0.1 
25.2% HNO3 0.64  ± 0.01 
15.1% HNO3 0.55 ± 0.05 
Table 15: Curve-adjusted concentrations of acid digested Au NPs. Concentrations are an average of 2 samples 
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4. Conclusion and Future Work 
I examined three parameters, the concentration of APTMS, the number of exposures of 2 
nm Au NPs, and the concentration of Gold Enhance
TM
 (GE) in the creation of Au-coated FexOy 
NPs. For these studies, two types of iron oxide nanoparticles were used: Kang NPs and Ferrotec 
NPs. Varying concentrations of APTMS were tested on Kang NPs and varying number of 
exposures of 2 nm Au NPs and concentrations of GE were tested on Ferrotec NPs. Ferrotec NPs 
were preferred because they more reliably have smaller initial sizes and less aggregation 
compared to Kang NPs.  
More coverage of ATPMS on the nanoparticles’ surface was found to lead to smaller 
nanoparticles. Variable concentrations of APTMS were tested on Kang NPs and should be tested 
on Ferrotec NPs as well. An amine assay would be a helpful analytical tool to determine the 
point of saturation of APTMS. Additionally, 2 exposures of 2 nm Au NPs yielded significantly 
smaller hydrodynamic diameters and should be further explored. An increasing number of 
exposures should be investigated (e.g. 3 exposures) in conjunction with an increasing 
concentration of APTMS until the nanoparticle surface is saturated with Au seeds. The effect of 
Gold Enhance
TM
 on particle size remains inconclusive. The optimal volume of Gold Enhance
TM
 
must be further tested. 
It was shown that the peak present in UV-Vis spectroscopy from 400–800 nm is that of 
Au-coated FexOy NPs. To test what concentrations of acid will not digest Au NPs, more runs 
must be done at concentrations of HNO3 between 15.1% and 7%. As this concentration becomes 
more precise, the specified concentration of acid must be tested on bare FexOy NPs to determine 
if the acid will digest them. 
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The synthesis protocol was standardized to allow for comparison across parameters. This 
will enable more strategic fine-tuning of the Au-FexOy synthesis. Moreover, syntheses must be 
repeated to ensure reproducibility, specifically with concern to optimizing the amount of Gold 
Enhance
TM
. After reproducibility of successful creation of NPs with a diameter of 40–70 nm and 
acid digestion of uncoated FexOy NPs, surface chemistry developed on 11.2 nm Au NPs should 




To construct the calibration curve, graph spectrum for each standard and find the two 
wavelengths that encase the metal’s primary (large) peak. Smaller, characteristic peaks may be 
included in this range if they appear in each of the standard’s spectrum. Make a line using these 
two points. Find the adjusted intensity of the primary peak by subtracting the y-value of the line 
at the peak wavelength from the intensity of that peak. Once this is done for all standards, make a 
scatter plot with these points. Note the R
2
 value and check to see it close to 1. If so, record the 
linear fit to be used for curve adjustments. If not, too many deviations are in the standard curve; 
run samples again. 
To calculate curve adjustments, first follow the same procedure to adjust the peak 
intensity. Plug the adjusted intensity into y of the linear fit. Find x, which is the concentration in 
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